IBDEI0JT ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9638,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,9638,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,9638,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,9639,0)
 ;;=180.9^^58^635^8
 ;;^UTILITY(U,$J,358.3,9639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9639,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,9639,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,9639,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,9640,0)
 ;;=203.02^^58^635^78
 ;;^UTILITY(U,$J,358.3,9640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9640,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,9640,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,9640,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,9641,0)
 ;;=V10.91^^58^635^44
 ;;^UTILITY(U,$J,358.3,9641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9641,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,9641,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,9641,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,9642,0)
 ;;=196.9^^58^635^62
 ;;^UTILITY(U,$J,358.3,9642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9642,1,4,0)
 ;;=4^196.9
 ;;^UTILITY(U,$J,358.3,9642,1,5,0)
 ;;=5^Lymph Nodes
 ;;^UTILITY(U,$J,358.3,9642,2)
 ;;=^267313
 ;;^UTILITY(U,$J,358.3,9643,0)
 ;;=204.90^^58^635^63
 ;;^UTILITY(U,$J,358.3,9643,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9643,1,4,0)
 ;;=4^204.90
 ;;^UTILITY(U,$J,358.3,9643,1,5,0)
 ;;=5^Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,9643,2)
 ;;=^336854
 ;;^UTILITY(U,$J,358.3,9644,0)
 ;;=V10.82^^58^635^42
 ;;^UTILITY(U,$J,358.3,9644,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9644,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,9644,1,5,0)
 ;;=5^H/O Malig Melanoma
 ;;^UTILITY(U,$J,358.3,9644,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,9645,0)
 ;;=198.4^^58^635^76
 ;;^UTILITY(U,$J,358.3,9645,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9645,1,4,0)
 ;;=4^198.4
 ;;^UTILITY(U,$J,358.3,9645,1,5,0)
 ;;=5^Mets to Nervous System
 ;;^UTILITY(U,$J,358.3,9645,2)
 ;;=^267335
 ;;^UTILITY(U,$J,358.3,9646,0)
 ;;=202.80^^58^635^80
 ;;^UTILITY(U,$J,358.3,9646,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9646,1,4,0)
 ;;=4^202.80
 ;;^UTILITY(U,$J,358.3,9646,1,5,0)
 ;;=5^Non-Hodgkin's Lymphoma
 ;;^UTILITY(U,$J,358.3,9646,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,9647,0)
 ;;=V10.02^^58^635^53
 ;;^UTILITY(U,$J,358.3,9647,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9647,1,4,0)
 ;;=4^V10.02
 ;;^UTILITY(U,$J,358.3,9647,1,5,0)
 ;;=5^H/O of Malig Oral/Pharynx
 ;;^UTILITY(U,$J,358.3,9647,2)
 ;;=^295204
 ;;^UTILITY(U,$J,358.3,9648,0)
 ;;=V10.43^^58^635^54
 ;;^UTILITY(U,$J,358.3,9648,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9648,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,9648,1,5,0)
 ;;=5^H/O of Malig Ovary
 ;;^UTILITY(U,$J,358.3,9648,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,9649,0)
 ;;=V10.46^^58^635^55
 ;;^UTILITY(U,$J,358.3,9649,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9649,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,9649,1,5,0)
 ;;=5^H/O of Malig Prostate
 ;;^UTILITY(U,$J,358.3,9649,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,9650,0)
 ;;=V10.06^^58^635^56
 ;;^UTILITY(U,$J,358.3,9650,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9650,1,4,0)
 ;;=4^V10.06
 ;;^UTILITY(U,$J,358.3,9650,1,5,0)
 ;;=5^H/O of Malig Rectum/Rectosigmoid/Anus
 ;;^UTILITY(U,$J,358.3,9650,2)
 ;;=^295208
 ;;^UTILITY(U,$J,358.3,9651,0)
 ;;=200.00^^58^635^81
 ;;^UTILITY(U,$J,358.3,9651,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9651,1,4,0)
 ;;=4^200.00
 ;;^UTILITY(U,$J,358.3,9651,1,5,0)
 ;;=5^Reticulosarcoma
 ;;^UTILITY(U,$J,358.3,9651,2)
 ;;=^72635
 ;;^UTILITY(U,$J,358.3,9652,0)
 ;;=V10.83^^58^635^57
 ;;^UTILITY(U,$J,358.3,9652,1,0)
 ;;=^358.31IA^5^2
